Look back at pharma news in week to June 29

By Barbara Obstoj-Cardwell. Editor

Last week’s clinical trial news included good and bad results. Roche’s latest data on Tecentriq was impressive in lung cancer, but Summit Therapeutics had a huge disappointment with its ezutromid in Duchenne muscular dystrophy (DMD). The US Food and Drug Administration’s approval of the first cannabinoid drug, GW Pharmaceuticals’ Epidiolex for rare forms of epilepsy caused a bit of s stir, while on the negative side, Pain Therapeutics looks set for another FDA rejection for pain drug Remoxy ER. On the M&A front, Novartis has at long last made a decision on the future of its eye care division Alcon.

Roche aims for first-mover edge in small cell lung cancer